Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset
-Vor Bio receives ex-Greater China rights to develop and commercialize telitacicept, a novel, dual-target recombinant fusion protein in global Phase 3 development for generalized myasthenia gravis
-RemeGen receives initial payment of $125 million consisting of an upfront payment of $45 million plus $80 million of warrants, potential regulatory and commercial milestones exceeding $4 billion, as well as tiered royalties
-Seasoned biopharma leader, Jean-Paul Kress, MD, appointed as Chief Executive Officer and Chairman of the Board, bringing proven track record in clinical development, commercialization, and strategic growth
CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Vor Bio, Inc. (Nasdaq: VOR) and RemeGen Co., Ltd. (HKEX: 9995, SHA: 688331) today announced entry into an exclusive license agreement granting Vor Bio global rights (excluding China, Hong Kong, Macau and Taiwan) to develop and commercialize telitacicept, a novel dual-target fusion protein approved in China for generalized myasthenia gravis (gMG), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). Under the terms of the agreement, Vor Bio will pay RemeGen an initial payment of $125 million consisting of an upfront payment of $45 million as well as $80 million of warrants to purchase common stock with an exercise price of $0.0001 per share. The agreement also provides for potential regulatory and commercial milestones exceeding $4 billion, in addition to tiered royalties.
Telitacicept is a novel, investigational fusion protein that targets key immune pathways involved in autoimmune disease. By selectively inhibiting BlyS (also known as BAFF) and APRIL - cytokines critical to B cell survival - telitacicept reduces autoreactive B cells and autoantibody production. RemeGen is conducting a global Phase 3 clinical trial which is now enrolling in the United States, Europe, and South America, with initial results expected in the first half of 2027.
Vor Bio also announced that its Board of Directors (the 'Board') has appointed Jean-Paul Kress, M.D., as Chief Executive Officer and Chairman of the Board, effective today. This follows Dr. Robert Ang's resignation from the positions of Chief Executive Officer and director earlier today. Dr. Ang will continue with Vor Bio as a strategic advisor to assist in the transition through October 2025. Dr. Kress's strategic vision and track record of transformative leadership position him to guide the company into its next phase of growth.
"I am absolutely thrilled to be leading Vor Bio as we transform the company to become a major player in autoimmune disease treatment," said Dr. Kress, Chairman and Chief Executive Officer, Vor Bio. "Targeting BAFF/APRIL signaling with telitacicept represents a significant advancement in addressing autoantibody driven diseases, which is highly differentiated from other modalities in this space. With a clinically advanced asset, we are uniquely positioned to develop this innovative therapy, with the goal of making a meaningful impact for patients living with autoimmune diseases around the world."
Dr. Kress brings decades of executive leadership experience in the pharmaceutical and biotech industries. He most recently served as Chief Executive Officer of MorphoSys, where he led the development, approval and commercialization of Monjuvi®️ (tafasitamab), and advanced the company's pipeline through the landmark acquisition of Constellation Pharmaceuticals in 2021, strengthening MorphoSys' position in oncology innovation and ultimately leading to its subsequent acquisition by Novartis in 2024. Prior to that, he was CEO of Syntimmune, guiding its lead immunology program through to acquisition by Alexion Pharmaceuticals. He currently serves on the Board of Sanofi S.A. and has held senior roles across leading biopharma companies.
'Today marks a transformative milestone for RemeGen and the global development of telitacicept,' said Dr. Jianmin Fang, CEO of RemeGen. 'The strategic out-licensing of telitacicept's ex-China rights accelerates our mission to deliver this innovative therapy to patients worldwide and will help maximize telitacicept's clinical and commercial potential on the global scale.'
About TelitaciceptTelitacicept is a novel, investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. In a Phase 3 clinical trial in generalized myasthenia gravis in China, telitacicept demonstrated a 4.8-point improvement in MG-ADL (Myasthenia Gravis Activities of Daily Living scale) vs. placebo at 24 weeks, the primary endpoint of the trial.
Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase 3 clinical trial in gMG is currently underway across the United States, Europe, and South America to support potential approval in the United States and Europe.
About Vor BioVor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.
About RemeGen Co. Ltd.
Founded in 2008, RemeGen is a leading biopharmaceutical company in China committed to providing solutions to the unmet clinical needs of patients suffering from life-threatening illnesses. RemeGen has research laboratories and offices in China and the United States. The company is committed to discovering, developing, and commercializing innovative and differentiated biologic drugs of significant clinical value in the key therapeutic areas of autoimmune, oncology, and ophthalmic diseases.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words 'aim,' 'anticipate,' 'can,' 'continue,' 'could,' 'design,' 'enable,' 'expect,' 'initiate,' 'intend,' 'may,' 'on-track,' 'ongoing,' 'plan,' 'potential,' 'should,' 'target,' 'update,' 'will,' 'would,' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio's statements regarding its plans for development and commercialization of telitacicept, the potential of telitacicept in various indications, the timing and pace of patient enrollment and dosing in clinical trials and the availability of data therefrom, the expected safety profile of telitacicept, the market opportunities for telitacicept and the ability of telitacicept to transform patient lives. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of Vor Bio's product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; uncertainties regarding regulatory approvals to conduct trials or to market products; and availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements and Vor Bio's ability to continue as a going concern. These and other risks are described in greater detail under the caption 'Risk Factors' included in Vor Bio's most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.
Contact:Investors & MediaSarah Spencer +1 857-242-6076sspencer@vorbio.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
42 minutes ago
- USA Today
US stock futures higher head of Senate vote on Trump bill
U.S. stock futures are higher as investors look to Congress' attempt to pass the One Big Beautiful Bill by the end of the week. Over the weekend, the Senate narrowly cleared a key procedural step to advance the mega tax bill. However, it still has a way to go to get through the Senate and to a House vote. Not all Republican senators are on board, and with such a slim majority, the bill will need almost every vote to pass. AT 6 a.m. ET, futures linked to the blue-chip Dow added 0.43%, while S&P 500 futures rose 0.37% and Nasdaq futures added 0.59%. The S&P 500 and Nasdaq are looking to extend gains from record highs scored at the end of the week to close the month strong. The S&P 500 is starting the week up 4.4% on the month, just lagging the Nasdaq's 6.1% gain in June. The Dow has added about 3.7% this month so far. Trade progress Investors initially cheered last week a breakthrough in trade talks with China. China agreed to approve export applications for rare earths to the U.S. Rare earths had been a sticking point between the two countries. China controls 90% of the world's most powerful rare-earth magnets, and Ford Motor recently had to curtail some production due to a magnet shortage. They also were relieved after the Trump administration signaled President Donald Trump's self-imposed July 9 deadline for countries to sign trade deals or face higher tariffs could be extended. If Trump extends the deadline, it could delay the inflation hike many economists are predicting would come with high tariffs. However, investors were reminded quickly that risks remain after Trump abruptly terminated talks with Canada over Canada's digital services tax. Trump said he would announce new tariffs on Canada within days. Canada is the U.S.' largest trading partners. Stocks initially fell on the Canada trade news, but it wasn't enough to push down stocks last week. Medora Lee is a money, markets, and personal finance reporter at USA TODAY. You can reach her at mjlee@ and subscribe to our free Daily Money newsletter for personal finance tips and business news every Monday through Friday.
Business Wire
an hour ago
- Business Wire
Ionic Digital Adds Michael Abbate and Oliver Wiener to Board of Directors
AUSTIN, Texas--(BUSINESS WIRE)--Ionic Digital Inc. ('Ionic' or the 'Company'), a prominent Bitcoin miner and emerging innovator in energy monetization, today announced that it has appointed Michael Abbate and Oliver Wiener, as new members of the Company's Board of Directors (the 'Board'). These appointments were made in connection with the settlement of pending litigation and pursuant to a cooperation agreement (the 'Agreement') entered into between the Company and Figure Markets Holdings Inc., GXD Labs LLC and certain stockholders of Ionic. Mr. Abbate was appointed as a Class I director with a term expiring at the 2025 Annual Meeting and has also been nominated by the Board to stand for re-election at the 2025 Annual Meeting along with existing Board Chair Elizabeth LaPuma. Mr. Wiener was appointed as a Class II director with a term expiring at the Company's 2026 annual stockholder meeting. 'We are pleased to have reached a constructive agreement to collectively help us achieve our mission to maximize value and provide a path toward shareholder liquidity,' said Elizabeth LaPuma, Chair of the Board. 'We believe this agreement serves the best interests of the Company and our stockholders and we look forward to working with the new members of the Board to build on the progress we have made.' The plaintiffs, Brett Perry, Christopher Villinger and Tony Vejseli said, 'Stockholders are thankful for Ms. LaPuma's diligence in working towards a comprehensive settlement that provides the Company with two highly qualified independent directors. We are excited to give Ionic a fresh start and look forward to seeing what this newly constituted Board can achieve for Ionic stockholders.' Pursuant to the Agreement, the counterparties have agreed to a customary standstill and voting agreement, among other provisions, each of which will remain in effect for 18 months following the execution of the Agreement. In connection with the Agreement, the notice of nomination of director candidates for the 2025 Annual Meeting previously submitted by certain of the counterparties has been withdrawn and the Company and the counterparties have agreed to settle all outstanding litigation. The 2025 Annual Meeting will be held at 9:00 a.m. Eastern Time on July 2, 2025. As a result of the Agreement, the election of directors at the 2025 Annual Meeting will no longer be a contested election. Only Mr. Abbate and Ms. LaPuma will be up for election at the 2025 Annual Meeting. Also as a result of the Agreement: (i) no proxies submitted pursuant to GOLD proxy cards will be voted at the 2025 Annual Meeting, (ii) no proxies submitted pursuant to WHITE proxy cards on or after June 30, 2025 will be voted at the 2025 Annual Meeting and (iii) proxies validly submitted pursuant to WHITE proxy cards on or before June 29, 2025 (i.e., which were postmarked on or prior to June 29, 2025 or were voted telephonically or electronically on or prior to June 29, 2025) will be continue to be voted in accordance with the instructions thereon (i.e., FOR or WITHHOLD with respect to Ms. LaPuma, with no votes cast with respect to Mr. Abbate), unless validly revoked or superseded. If you (i) did not vote prior to June 30, 2025 and wish to vote, (ii) voted pursuant to a WHITE proxy card on or prior to June 29, 2025 and wish to change your vote or (iii) previously voted pursuant to a GOLD proxy card and wish to vote, you may only do so by virtually attending the 2025 Annual Meeting on July 2, 2025 and downloading, completing and signing the PDF ballot that will be made available on the meeting website platform approximately 15 minutes prior to the start of the 2025 Annual Meeting and returning the same to the Company's Inspector of Elections prior to the closing of the polls at the 2025 Annual Meeting. Stockholders voting live at the 2025 Annual Meeting will be able to cast votes 'FOR' or 'WITHHOLD' with respect to each of Ms. LaPuma and Mr. Abbate. The Company recommends that all stockholders attend the meeting virtually and vote 'FOR' each of Ms. LaPuma and Mr. Abbate, irrespective of whether they previously submitted a proxy card, as voting live at the 2025 Annual Meeting is the only way to cast a vote in favor of the election of each of Ms. LaPuma and Mr. Abbate. Stockholders are also advised to visit the Company's website for the 2025 annual meeting at and read the updated FAQs, which contain additional important information, including with respect to voting. White & Case LLP and Potter Anderson & Corroon LLP are serving as legal counsel to Ionic. Olshan Frome Wolosky LLP and Abrams & Bayliss LLP are serving as legal counsel to Figure Markets Holdings Inc., GXD Labs LLC and certain plaintiff stockholders of Ionic. Ionic Digital is a prominent Bitcoin miner and emerging innovator in energy monetization. With facilities across the United States and a total capacity of 394 megawatts, Ionic expects to drive the next generation of energy efficient, low-cost computing through sustainable Bitcoin mining. The Company's strategic initiatives focus on operational efficiency, transparency, and securing long-term financial growth for its investors. For more information, visit and follow us on X at @IonicDigital.
Business Upturn
an hour ago
- Business Upturn
Upwork Establishes Economic Advisory Council to Deepen Understanding of AI's Impact on Work
By GlobeNewswire Published on June 30, 2025, 13:25 IST Council brings together leading academics from MIT, Stanford and Georgetown to advise on AI-human workforce design, identify labor market shifts, and guide Upwork's AI-powered evolution PALO ALTO, Calif., June 30, 2025 (GLOBE NEWSWIRE) — Upwork Inc. (Nasdaq: UPWK), the world's work marketplace, today announced the formation of the Upwork Economic Advisory Council, a group of preeminent economists, scientists, and researchers who will provide strategic guidance to the company as it advances its human and AI-powered platform to better serve customers around the world in getting work done. As AI reshapes industries and workforces globally, the Upwork Economic Advisory Council will offer critical insight into the economic, social, and ethical implications of AI's rapid integration into work and the workforce, ensuring Upwork's innovations in the space are grounded in rigorous, real-world research. With millions of interactions and transactions taking place each year, Upwork's platform offers one of the most comprehensive views into how work is evolving. As a self-contained labor marketplace with $4 billion in gross services volume (GSV) in 2024 alone, activity on the platform often serves as an early indicator of broader labor market trends. Upwork's latest research on how AI is reshaping work is available here . 'Work is being reshaped by AI,' said Hayden Brown, president and CEO of Upwork. 'By assembling the best minds at the intersection of economics, technology, and business management, we are advancing our commitment to create opportunity for our customers by building the next frontier of human and AI-powered flexible work. Our dynamic marketplace and cutting-edge technology uniquely position us to be a pioneer, and this Council will only further that work.' The Economic Advisory Council spans expertise across labor economics, marketplace design, organizational productivity, behavioral science, and technology. Members include: Dr. Nicholas Bloom, professor of economics at Stanford University and senior fellow at the Stanford Institute for Economic Policy Research (SIEPR). Bloom's research focuses on management practices, productivity measurement, and organizational behavior, with recent studies exploring the future of remote work and AI's impact on workplace dynamics. professor of economics at Stanford University and senior fellow at the Stanford Institute for Economic Policy Research (SIEPR). Bloom's research focuses on management practices, productivity measurement, and organizational behavior, with recent studies exploring the future of remote work and AI's impact on workplace dynamics. Dr. John Horton, associate professor at the MIT Sloan School of Management and faculty research fellow at the National Bureau of Economic Research (NBER). Horton's research focuses on information systems, market design, labor economics, organizational dynamics, and the effects of AI on labor markets. associate professor at the MIT Sloan School of Management and faculty research fellow at the National Bureau of Economic Research (NBER). Horton's research focuses on information systems, market design, labor economics, organizational dynamics, and the effects of AI on labor markets. Dr. Kelly Monahan, managing director of the Upwork Research Institute. Monahan studies and writes on emerging technologies, workforce transformation, and the integration of non-traditional talent models like freelancing, with particular emphasis on human-centric approaches to AI adoption and organizational design. managing director of the Upwork Research Institute. Monahan studies and writes on emerging technologies, workforce transformation, and the integration of non-traditional talent models like freelancing, with particular emphasis on human-centric approaches to AI adoption and organizational design. Dr. Sendhil Mullainathan, professor in the Department of Economics and the Department of Electrical Engineering and Computer Science at MIT. Mullainathan's research applies machine learning to complex problems in human behavior, social policy, and medicine. professor in the Department of Economics and the Department of Electrical Engineering and Computer Science at MIT. Mullainathan's research applies machine learning to complex problems in human behavior, social policy, and medicine. Dr. Dewey Murdick, executive director of Georgetown University's Center for Security and Emerging Technology (CSET). Murdick specializes in technology foresight, AI policy, and data science, with a focus on how emerging technologies reshape labor markets and societal structures. executive director of Georgetown University's Center for Security and Emerging Technology (CSET). Murdick specializes in technology foresight, AI policy, and data science, with a focus on how emerging technologies reshape labor markets and societal structures. Dr. Andrew Rabinovich, VP of artificial intelligence and machine learning at Upwork. Rabinovich leads Upwork's AI transformation strategy, drawing on over two decades of expertise in machine learning and computer vision. Rabinovich's research primarily focuses on computer vision, multimodal learning, and structured deep learning architectures. VP of artificial intelligence and machine learning at Upwork. Rabinovich leads Upwork's AI transformation strategy, drawing on over two decades of expertise in machine learning and computer vision. Rabinovich's research primarily focuses on computer vision, multimodal learning, and structured deep learning architectures. Dr. Melissa Valentine, associate professor of management science and engineering at Stanford University and senior fellow at the Stanford Institute for Human-Centered AI. Valentine's research examines how AI and algorithmic systems transform collaboration, organizational design, and workforce structures. The council's mandate is to: Advise on frameworks to measure productivity, performance, and economic value in AI-enabled work. Guide the integration of ethical and economic principles into AI-driven marketplace evolution. Identify early indicators of labor market shifts driven by AI adoption. Provide strategic insight into emerging skills and talent supply trends. Collaborate on research and thought leadership. 'Academic research in artificial intelligence has exploded, quadrupling since 2015, yet work at the intersection of AI and labor markets remains limited,' said Dr. Kelly Monahan, managing director of the Upwork Research Institute. 'Our Economic Advisory Council aims to close that gap, translating cutting-edge research into practical applications that protect human agency, ensure marketplace trust, and expand opportunity in an AI-enabled future.' Upwork's new council underscores the company's broader commitment to human-centered, responsible AI innovation. To learn more about the council's work and members, visit the Upwork Research Institute: . About Upwork Upwork is the world's largest work marketplace that connects businesses with highly skilled, AI-enabled independent talent from across the globe. From entrepreneurs to Fortune 100 enterprises, companies rely on Upwork's trusted platform and its mindful AI companion, Uma, to find and hire expert talent, leverage AI-powered work solutions, and drive business transformation. With on-demand access to professionals spanning more than 10,000 skills across AI & machine learning, software development, sales & marketing, customer support, finance & accounting, and more, Upwork enables businesses of all sizes to scale, innovate, and build agile teams for the age of AI and beyond. Upwork's platform has facilitated more than $25 billion in economic opportunity for talent around the world. Learn more at and follow us on LinkedIn , Facebook , Instagram , TikTok , and X . Contact:Christine Lee [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
